Capricor Therapeutics met with the FDA last week for a type A meeting, during which CEO Linda Marbán aimed to explain to the ...

VantAI will use its machine learning capabilities to identify novel target-effector pairs that Halda can use in designing its ...

In late May, a patient died after receiving Rocket Pharmaceuticals' investigational gene therapy for Danon disease, spurring ...

A draft copy of an upcoming MAHA report reveals a strategy in lockstep with recent HHS actions such as reviving the Task ...

The FDA recommends that companies use overall survival as a primary endpoint for clinical trials where feasible. The new ...

Drugs are being invented and manufactured right here in the U.S. by Americans, for Americans. So why doesn’t the industry ...

With its structural changes, CSL expects to generate $500 to $550 million in annualized savings over the next three years.

The platform strategy of using one molecule to target an underlying biological pathway to address many different diseases can ...

Media coverage can help biopharma executives connect with, inform and inspire the public. In this column, ...

Regulations aiming to lower the cost of vital medicines will instead end up restricting access and disincentivizing R&D.

The Trump administration's ever-changing tariffs and Most Favored Nation drug pricing are part of a blizzard of unclear, ...

The CDC no longer recommends COVID-19 vaccines for healthy children and healthy pregnant women, a position that has been opposed by leading medical societies.